Latest Dyax Corp (DYAX) Headlines
27.7% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Wed Mar 12, 5:05PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 27.74% as of today's recent price of $10.43.
Uptrend Call Working As Dyax Stock Rises 28.1% (DYAX)
Comtex SmarTrend(R) - Wed Mar 05, 11:11AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 28.11% as of today's recent price of $10.46.
Dyax Corp. Announces Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Fri Feb 28, 6:00AM CST
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2013. Dyax will host a webcast and conference call at 8:30 a.m. (ET) today to review financial results and provide updates regarding its key value drivers - the hereditary angioedema (HAE) business, including KALBITOR(R) (ecallantide) and DX-2930, and the Licensing and Funded Research Portfolio (LFRP).
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 27, 12:41PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Dyax Corp. (DYAX) Soars: Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:39AM CST
Dyax Corp. was a big mover last session, as its shares rose nearly 7% on the day.
Dyax Corp. to Participate in the 2014 Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 3:01PM CST
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 2014 Cowen and Company 34th Annual Health Care Conference being held March 3-5, 2014 at the Boston Marriott Copley Place in Boston, MA. The Company will present on Monday, March 3 at 3:30 PM (ET) and will provide a corporate update on Dyax's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.
Dyax Up 32.9% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Wed Feb 26, 9:48AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 32.88% as of today's recent price of $10.85.
Dyax Announces Positive Results from Phase 1a Clinical Trial of DX-2930
Business Wire - Tue Feb 25, 3:01PM CST
--Management to Host Conference Call with Detailed Data Presentation Today at 5:00 p.m. ET
Lilly Drug Ramucirumab Boosts Lung Cancer Survival
at Investor's Business Daily - Wed Feb 19, 10:02AM CST
Big pharma Eli Lilly (LLY) said Wednesday that its drug candidate ramucirumab improved the survival of lung-cancer patients in a late-stage study. Lilly stock gapped up 3% in early trading on the stock market today. The study looked at patients with...
18.6% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Wed Feb 19, 9:20AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on January 10th, 2014 at $8.17. In approximately 1 month, Dyax has returned 18.62% as of today's recent price of $9.69.
Dyax Corp. to Host Fourth Quarter and Year End 2013 Earnings Call and Webcast
Business Wire - Thu Feb 13, 12:30PM CST
Dyax Corp. (NASDAQ YAX) will host a webcast and conference call, including an open question and answer session, Friday, February 28, 2014. During the call, management will discuss the Company's financial results for the fourth quarter and full year 2013 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.
Fagerhult: Year-End Report 2013
Business Wire - Thu Feb 13, 5:52AM CST
Regulatory News:
Dyax Corp. to Participate in the 2014 Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 7:00AM CST
Dyax Corp. (NASDAQ YAX) announced today that executive management will participate in the 2014 Leerink Global Healthcare Conference being held February 12-13, 2014 at the Waldorf Astoria in New York City. On Wednesday, February 12 at 11:05AM (ET), Gustav Christensen, President and Chief Executive Officer, will participate in a fireside chat to discuss the Company's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.
The Simplest Non-Fad Diet Book You'll Ever Digest
PR Newswire - Thu Jan 23, 7:00AM CST
A poor diet speeds the effects of aging, derails metabolism and induces weight gain. "Maximized Metabolics," the latest book by New York Times best-selling author Dr. Ben Lerner gives readers the tools to maximize their metabolism and sidestep the early onset of aging.
Healthcare Companies Report Stock Price Movement, Conference Call Schedules, Study Results, and Presentations - Research Report on Merck, Keryx Biopharma, Pacira, Ligand Pharma, and Dyax
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Use Options For A Chance To Buy DYAX At A 40% Discount
at The Street - Thu Dec 12, 10:43AM CST
Looking back to 64 days ago, Dyax Corp priced a 9,230,770 share secondary stock offering at $6.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time...
Stock Price Movements, Share Repurchase Programs, and Regulatory Submissions - Research Report on Viropharma, Santarus, Cyberonics, Pacira Pharmaceuticals, and Dyax
PR Newswire - Tue Dec 10, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Insider Trading Alert - PACW, DYAX, YELP, SYK And NUAN Traded By Insiders
at The Street - Mon Dec 09, 11:03AM CST
Stocks with insider trader activity include PACW, DYAX, YELP, SYK and NUAN
27.7% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Wed Mar 12, 5:05PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 27.74% as of today's recent price of $10.43. Uptrend Call Working As Dyax Stock Rises 28.1% (DYAX)
Comtex SmarTrend(R) - Wed Mar 05, 11:11AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 28.11% as of today's recent price of $10.46. Dyax Corp. Announces Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Fri Feb 28, 6:00AM CST
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2013. Dyax will host a webcast and conference call at 8:30 a.m. (ET) today to review financial results and provide updates regarding its key value drivers - the hereditary angioedema (HAE) business, including KALBITOR(R) (ecallantide) and DX-2930, and the Licensing and Funded Research Portfolio (LFRP).
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 27, 12:41PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Dyax Corp. (DYAX) Soars: Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:39AM CST
Dyax Corp. was a big mover last session, as its shares rose nearly 7% on the day.
Dyax Corp. to Participate in the 2014 Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 3:01PM CST
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 2014 Cowen and Company 34th Annual Health Care Conference being held March 3-5, 2014 at the Boston Marriott Copley Place in Boston, MA. The Company will present on Monday, March 3 at 3:30 PM (ET) and will provide a corporate update on Dyax's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.
Dyax Up 32.9% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Wed Feb 26, 9:48AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 32.88% as of today's recent price of $10.85. Dyax Announces Positive Results from Phase 1a Clinical Trial of DX-2930
Business Wire - Tue Feb 25, 3:01PM CST
--Management to Host Conference Call with Detailed Data Presentation Today at 5:00 p.m. ET
Lilly Drug Ramucirumab Boosts Lung Cancer Survival
at Investor's Business Daily - Wed Feb 19, 10:02AM CST
Big pharma Eli Lilly (LLY) said Wednesday that its drug candidate ramucirumab improved the survival of lung-cancer patients in a late-stage study. Lilly stock gapped up 3% in early trading on the stock market today. The study looked at patients with...
18.6% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Wed Feb 19, 9:20AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on January 10th, 2014 at $8.17. In approximately 1 month, Dyax has returned 18.62% as of today's recent price of $9.69. Dyax Corp. to Host Fourth Quarter and Year End 2013 Earnings Call and Webcast
Business Wire - Thu Feb 13, 12:30PM CST
Dyax Corp. (NASDAQ
YAX) will host a webcast and conference call, including an open question and answer session, Friday, February 28, 2014. During the call, management will discuss the Company's financial results for the fourth quarter and full year 2013 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio. Fagerhult: Year-End Report 2013
Business Wire - Thu Feb 13, 5:52AM CST
Regulatory News:
Dyax Corp. to Participate in the 2014 Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 7:00AM CST
Dyax Corp. (NASDAQ
YAX) announced today that executive management will participate in the 2014 Leerink Global Healthcare Conference being held February 12-13, 2014 at the Waldorf Astoria in New York City. On Wednesday, February 12 at 11:05AM (ET), Gustav Christensen, President and Chief Executive Officer, will participate in a fireside chat to discuss the Company's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio. The Simplest Non-Fad Diet Book You'll Ever Digest
PR Newswire - Thu Jan 23, 7:00AM CST
A poor diet speeds the effects of aging, derails metabolism and induces weight gain. "Maximized Metabolics," the latest book by New York Times best-selling author Dr. Ben Lerner gives readers the tools to maximize their metabolism and sidestep the early onset of aging.
Healthcare Companies Report Stock Price Movement, Conference Call Schedules, Study Results, and Presentations - Research Report on Merck, Keryx Biopharma, Pacira, Ligand Pharma, and Dyax
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Use Options For A Chance To Buy DYAX At A 40% Discount
at The Street - Thu Dec 12, 10:43AM CST
Looking back to 64 days ago, Dyax Corp priced a 9,230,770 share secondary stock offering at $6.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time...
Stock Price Movements, Share Repurchase Programs, and Regulatory Submissions - Research Report on Viropharma, Santarus, Cyberonics, Pacira Pharmaceuticals, and Dyax
PR Newswire - Tue Dec 10, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Insider Trading Alert - PACW, DYAX, YELP, SYK And NUAN Traded By Insiders
at The Street - Mon Dec 09, 11:03AM CST
Stocks with insider trader activity include PACW, DYAX, YELP, SYK and NUAN
